Visitor publication

New progress in myopia prevention and control: caffeine metabolites may slow the progression of myopia in children

Posting time:2022-10-06 02:43:02

New progress in myopia prevention and control: caffeine metabolites may slow the progression of myopia in children

Editor's Note The excessive stretching and thinning of the retina, retinal pigment epithelium, and choroid associated with myopia can lead to complications such as retinal detachment, myopic macular degeneration, and glaucoma. Myopia usually begins at the age of 6-7 and progresses to the age of 16-20. Currently available pharmacological and optical interventions cannot completely prevent the development of myopia. An observational study published online in the British Journal of Ophthalmology suggests that a caffeine metabolite called 7-methylxanthine (7-MX) may slow the progression of myopia in children. If 7-MX proves to be safe and effective in large clinical trials, it could be a valuable treatment for myopia, the researchers said. New study: Understanding the rate of myopia progression in children taking 7-MX Since 2009, Denmark has used 7-MX to treat myopia in children. But until now, 7-MX has not been fully evaluated in long-term studies, and researchers conducted a related study to understand the rate of myopia progression in children taking 7-MX. The researchers selected the medical records of 711 children (356 girls and 355 boys) who were treated for myopia at an eye clinic in Denmark between June 2000 and January 2021. Among them, 624 children took up to 1200㎎ 7-MX tablets per day (average 470㎎), while 87 children did not take 7-MX tablets for various reasons. The 7-MX dose and the 6-year simulated association between myopia progression and axial lengthening The average age at initiation of treatment was 11 years (range, 7-15 years) in children who underwent comprehensive eye testing. , including measuring axial length, and tracking eye length and myopia for an average of 3.5 years (range, 11 months to 9 years). The study found that children started with an average refractive error (myopia) of -2.43D, which increased by an average of 1.34D during the monitoring period. Treatment with 7-MX is associated with a reduction in the rate of myopia progression (PP). Based on these data, the researchers modeled: For a 7-year-old child with a typical refractive error of -2.53D, without treatment, the child's The degree of myopia will increase by -3.49D, and the axial length of the eye will increase by 1.80mm; if 1000㎎7-MX is taken every day, the child's myopia will increase by -2.65D, and the axial length of the eye will increase by 1.63mm. For 11-year-old children, if not After treatment, in the next 6 years, the child's myopia will increase by -2.27D, and the axial length of the eye will increase by 1.01mm; if 1000㎎7-MX is taken every day, the child's myopia will increase by -1.43D, and the axial length of the eye will increase by -1.43D. An increase of 0.84mm. In addition, during the monitoring period, none of the children taking 7-MX reported any side effects. Conclusions The findings suggest that the dose of 7-MX children received was associated with myopia progression. The researchers also noted that the study was observational , and could not explain potential influencing factors, such as genetic factors, time spent outdoors, ethnicity, and time spent working in close proximity. Therefore, the findings cannot establish cause and effect. Cause and effect and treatment effects can only be determined through randomized trials. Existing Myopia control interventions are not completely effective in preventing children from developing high myopia, and if causality and efficacy can be demonstrated in future randomized controlled trials, 7-MX may become a valuable complementary treatment. References: Trier K, Cui D, Ribel-Madsen S, et alOral administration of caffeine metabolite 7-methylxanthine is associated with slowed myopia progression in Danish childrenBritish Journal of Ophthalmology Published Online First: 22 August 2022. doi: 10.1136/bjo-2021-320920

Top ranking

Links